Kimiara company organized a febuxostat advisory board meeting for the first time in Iran with the presence of rheumatology, nephrology and cardiology field veterans on Thursday 28th of December, 2023.
Precious professors:
Rheumatologists: Dr. Mohsen Soroush, President of the Iranian Rheumatology Association, Dr. Reza Najafizadeh, Dr. Arman Ahmadzadeh, Chief Inspector of the Rheumatology Association, and Dr. Anousheh Haghighi.
Nephrologists: Dr. Moniralsadat Hakemi, Dr. Farhanaz Dadras and Dr. Hassan Argani, Dr. Jamshid Rouzbeh and heart failure specialist: Dr. Farah Naqashzadeh attended in this meeting.
In this scientific session, the main position of the febuxostat molecule as a new and superior blood uric acid-lowering treatment in gout disease by presenting a treatment protocol based on the ACR 2020 guideline as the first line of treatment, as well as the profile of different hyperurecemic patients without clinical symptoms in high-risk patients such as: kidney failure in stages 3 to 5, pre-dialysis stage or stage 5, as well as dialysis, heart surgery, heart failure, high BMI with hypercholesterolemia and hypertriglyceridemia, diabetes, kidney transplant, kidney stones, tumor lysis syndrome in Cancer patients and the topic of switching were raised based on latest articles.
In the continuation of this session, respected professors, considering the comparison of the superiority of febuxostat over allopurinol as a fast and strong blood uric acid lowering agent, antioxidant, antiatherogenic effects, strong cardio-cerebro and reno protection and a strong blood lipid lowering with high safety of febuxostat compared to allopurinol, they agreed on the administration of febuxostat as the first choice in the treatment of symptomatic and non-symptomatic hyperuricemia to prevent various renal and cardiovascular events.
Also, the bioequivalence studies of febuxostat molecule (Febix) manufactured brand of Kimiaara company with Adenoric brand of Menarini company were investigated, and the results show that Febix is therapeutically equivalent to the originator, the febuxostat of Menarini company according to the bioequivalence studies approved by FDA.
